Thomas Dyrberg
BOARD OF DIRECTORS
Pharmaceutical Sciences
Galera Therapeutics Inc.
United States of America
Biography
Dr. Dyrberg is Managing Partner at Novo A/S. He is a member of the Boards of Directors of Delenex Therapeutics AG, Nuvelution Pharma, Inc., Ophthotech Corporation, PanOptica Inc., and Veloxis Pharmaceuticals A/S. Dr. Dyrberg held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, CA, USA. In 1990, he joined Novo Nordisk A/S, initially working in health care discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in health care clinical drug development. Dr. Dryberg attended the University of Copenhagen, where he obtained an MD degree and a DMSc degree.
Research Interest
Host defense mechanisms,LPS effects on neurotransmitters
